Among the top clinical and translational researchers who will speak at the symposium there are L. Baker, R. Benjamin, E. de Alava, P. Hogendoorn, G. Demetri, J. Fletcher, L. Helman, M. Ladanyi, R. Maki.
The highly qualified Symposium Faculty, made up of some of the most eminent experts in the field of sarcoma treatment and research, has also organized a two-day closed meeting before the event to discuss ideas for future research projects.
The ESMO Symposium on Sarcoma and GIST is supported by two pharmaceutical companies -- Novartis Oncology and PharmaMar -- and by Conticanet, a EU-funded project for clinical research on soft tissue sarcomas in Europe, whose coordinator, Dr. Jean-Yves Blay, is one program co-chair. The event has been organized also in cooperation with the Milan Istituto Nazionale Tumori, a referral institute for sarcomas and GIST.
"ESMO is dedicated to educating and supporting oncologists, also when it comes to the treatment of specific disease areas such as sarcoma," said Prof. Rolf A. Stahel, Chair of the ESMO Educational Committee.
In line with its commitment to educate and guarantee the best possible treatment to all cancer patients, later this year ESMO will be hosting an event dedicated to rare tumors in Brussels, 'Rare Tumors in Europe: Challenges and Solutions'.
"Sarcomas being rare cancers make this meeting a significant expression of ESMO's efforts on rare diseases," said Dr. Casali. Rare tumors are classified as such if considered individually, but represent collectively one-fourth of all cancer cases. "People with rare diseases have the same right to receive proper treatment as al
|Contact: Vanessa Pavinato|
European Society for Medical Oncology